# Avatrombopag for Chemotherapy-induced Thrombocytopenia

> **NCT05218226** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 50 (estimated)

## Conditions studied

- Chemotherapy-induced Thrombocytopenia
- Avatrombopag

## Interventions

- **DRUG:** Avatrombopag

## Key facts

- **NCT ID:** NCT05218226
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-10
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-02-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05218226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05218226, "Avatrombopag for Chemotherapy-induced Thrombocytopenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05218226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*